Elena S. Malova

Elena S. Malova

Auto-generated profile, based on publicly available information

Elena S. Malova

Medical University “Reaviz

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
IBIrina P Balmasova
Irina P Balmasova
NYNikolay D Yushchuk
Nikolay D Yushchuk
OMOspan A Mynbaev
Ospan A Mynbaev
NANageswara R Alla
Nageswara R Alla
EMElena S Malova
Elena S Malova
CGChang-Lu Gao
Chang-Lu Gao
Chronic hepatitis B (CHB) is a widespread infectious disease with unfavorable outcomes and life-threatening consequences for patients, in spite of modern vaccination and antiviral treatment modalities. Cutting-edge experimental approaches have demonstrated key pathways that involve cross-talk between viral particles and host immune cells. All events, including penetration of hepatitis B virus (HBV) particles into host cells, establishing persistence, and chronization of CHB infection, and possibility of complete elimination of HBV particles are controlled by the immune system. Researchers have paid special attention to the replication capacity of HBV in host cells, which is associated with cellular changes that reflect presentation of viral antigens and variability of HBV antigen features. In addition, specific HBV proteins have an immune-modulating ability to initiate molecular mechanisms that “avoid” control by the immune system. The relationship between immunological shifts and chronic infection stages has been intensively studied since it was recognized that the immune system is a direct participant in the recurrent (cyclic) nature of CHB. Understanding the wide diversity of molecular pathways and the crosstalk between innate and adaptive immune system components will provide fresh insight into CHB immune pathogenesis and the possibilities of developing new treatment strategies for this disease.

1 January 2023 in Immunologiya
Verified
Journal Article
Closed access
SFSamara State Medical University of the Ministry of Health of the Russian Federation
Samara State Medical University of the Ministry of Health of the Russian Federation
MIM.F. Ivanov
M.F. Ivanov
IBI.P. Balmasova
I.P. Balmasova
AZA.V. Zhestkov
A.V. Zhestkov
DKD.YU. Konstantinov
D.YU. Konstantinov
S«Samara Limited Liability Medical Company «Hepatologist»
Samara Limited Liability Medical Company «Hepatologist»
Экспрессия NKG2D цитотоксическими Т-лимфоцитами как возможный механизм иммунопатогенеза геморрагической лихорадки с почечным синдромом

1 January 2020 in Immunologiya
Verified
Journal Article
Closed access
IBI.P. Balmasova
I.P. Balmasova
VTV.N. Tsarev
V.N. Tsarev
EYE.N. Yushchuk
E.N. Yushchuk
ADA.S. Dorovskikh
A.S. Dorovskikh
EME.S. Malova
E.S. Malova
SAS.D. Arutyunov
S.D. Arutyunov

8 October 2014
Verified
Journal Article
Closed access
IBI P Balmasova
I P Balmasova
RSR I Sepiashvili
R I Sepiashvili
ISIa R Sepiashvili
Ia R Sepiashvili
EME S Malova
E S Malova

1 January 2023 in Immunologiya
Verified
Journal Article
Closed access
SFSamara State Medical University of the Ministry of Health of the Russian Federation
Samara State Medical University of the Ministry of Health of the Russian Federation
MIM.F. Ivanov
M.F. Ivanov
IBI.P. Balmasova
I.P. Balmasova
AZA.V. Zhestkov
A.V. Zhestkov
DKD.YU. Konstantinov
D.YU. Konstantinov
S«Samara Limited Liability Medical Company «Hepatologist»
Samara Limited Liability Medical Company «Hepatologist»
Прогностическое значение фенотипических изменений лимфоцитов при геморрагической лихорадке с почечным синдромом

24 September 2023 in Clinical Dentistry (Russia)
Verified
Journal Article
Open access
PDF file
ИБИ.п. Балмасова
И.п. Балмасова
ВЦВ.н. Царев
В.н. Царев
РГР.ш. Гветадзе
Р.ш. Гветадзе
МММ.ш. Мустафаев
М.ш. Мустафаев
ТЦТ.в. Царева
Т.в. Царева
SASergey Arutyunov
Sergey Arutyunov
Виром полости рта человека — составная часть микробиома как сообщества микроорганизмов, населяющих полость рта, включает вирусы эукариот, персистирующие в организме человека, и вирусы прокариот (бактериофаги). Виром выполняет важнейшие физиологические функции по защите организма человека от патогенов через контроль состава микробиома, влияние на формирование биопленок, иммуномодулирующие эффекты, играет огромную роль в эволюции человека в целом, но нередко служит источником тяжелых заболеваний. Среди вирусов, населяющих полость рта, ведущая роль в развитии патологических состояний этой локализации, в частности заболеваний пародонта, принадлежит герпесвирусам (вирусу Эпштейна—Барр, цитомегаловирусу), этиопатогенетическое значение которых расшифровано лишь отчасти и его предстоит уточнить. С другой стороны, вирусы можно использовать как полезные агенты в борьбе с заболеваниями полости рта, в частности перспективно применение бактериофагов, хотя условия и варианты их использования нуждаются в дальнейшем изучении. The human oral virome is a part of the microbiome as a community of microorganisms inhabiting the oral cavity, includes eukaryotic viruses that persist in the human body and microbial viruses (bacteriophages). Virome performs the most important physiological functions to protect the human body from pathogens through the control of the microbiome composition, the impact on the formation of biofilms, immunomodulatory effects, plays a huge role in the human evolution as a whole, but often serves as a source of serious diseases. Among the eukaryotic viruses inhabiting the oral cavity, the leading role in the development of pathological conditions of this localization, in particular, periodontal diseases, belongs to herpesviruses (Epstein—Barr virus, cytomegalovirus), the etiopathogenetic significance of which is only partially deciphered and it remains to be clarified. In the fight against diseases of the oral cavity, the use of bacteriophages is promising, although the conditions and variants for their use need further study.